Anna Kiialainen

Basel, BS 4070, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

One-stage Assay Factor VIII Activity Reflects AAV-Derived Factor VIII-Enhanced Thrombin Activation and Predicts Phenotype.

One-stage Assay Factor VIII Activity Reflects AAV-Derived Factor VIII-Enhanced Thrombin Activation and Predicts Phenotype.

Journal: Blood

Published: December 22, 2025

Emicizumab prophylaxis in children with hemophilia A with factor VIII inhibitors in China (HAVEN 5).

Emicizumab prophylaxis in children with hemophilia A with factor VIII inhibitors in China (HAVEN 5).

Journal: Chinese medical journal

Published: October 16, 2025

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.

Journal: American journal of hematology

Published: February 29, 2024

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.

Journal: Blood

Published: October 10, 2023

Clinical pharmacology of emicizumab for the treatment of hemophilia A.

Clinical pharmacology of emicizumab for the treatment of hemophilia A.

Journal: Expert review of clinical pharmacology

Published: August 02, 2023

Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.

Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.

Journal: Research and practice in thrombosis and haemostasis

Published: April 18, 2023

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: March 29, 2022

Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY).

Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY).

Journal: Research and practice in thrombosis and haemostasis

Published: March 24, 2022

Low immunogenicity of emicizumab in persons with haemophilia A.

Low immunogenicity of emicizumab in persons with haemophilia A.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: June 11, 2021

Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.

Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.

Journal: British journal of haematology

Published: May 19, 2021

Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high-dose bypassing agents in the HAVEN 1 study.

Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high-dose bypassing agents in the HAVEN 1 study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: May 01, 2020

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects.

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects.

Journal: Clinical pharmacology in drug development

Published: December 18, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026